Amsterdam

• Phase III study of Pembrolizumab plus chemoradiation vs chemoradiation along for patients with muscle invasive bladder cancer Ended recruitment
  2023-503500-87-00 11 2020-03-17 Muscle Invasive Bladder Cancer
• A Phase 3 Trial Comparing Selpercatinib to Cabozantinib or Vandetanib in Patients with RET-Mutant Medullary Thyroid Cancer Ended recruitment
  2023-506782-56-00 5 2020-03-10 RET-Mutant Medullary Thyroid Cancer
• A multicenter trial assessing the impact of lipoprotein (a) lowering with pelacarsen (TQJ230) on major cardiovascular events in patients wit … Ended recruitment
  2023-508292-37-00 5 2020-03-06 Cardiovascular Disease
• A Phase 1b Study of Subcutaneous Daratumumab Regimens in Combination with Bispecific T Cell Redirection Antibodies for the Treatment of Subj … Ended recruitment
  2023-503468-17-00 3 2020-03-02 Multiple myeloma
• A Phase 3 Trial Comparing Selpercatinib to Platinum-Based and Pemetrexed Therapy with or without Pembrolizumab (LIBRETTO-431) Ended recruitment
  2023-506783-14-00 5 2020-02-24 Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
• Immune induction strategies to improve response to immune checkpoint blockade in triple negative breast cancer (TNBC) patients: the TONIC-2 … Ended recruitment
  2024-513217-12-00 4 2020-02-04 Triple negative breast cancer (TNBC) with metastatic disease
• An Open Label Study of JNJ-68284528, Directed Against BCMA in Subjects with Multiple Myeloma Ended recruitment
  2023-506587-13-00 4 2020-01-30 Multiple Myeloma
• A Randomized Controlled Phase II Clinical Trial with Intradermal IMO-2125 (Tilsotolimod) in pT3-4 cN0M0 Melanoma (Intrim 1 study) Ended recruitment
  2023-509461-20-00 4 2020-01-22 pT3-4 cN0M0 Melanoma
• A clinical trial to judge the safety, tolerability and effects on abnormal bone formation of reseach medication AZD 0530 (sarcatinib) in pat … Ended recruitment
  2024-515186-33-00 4 2020-01-08 Fibrodyplasia Ossificans Progressiva (FOP)
• Phase III randomized clinical trial for stage III epithelial ovarian cancer randomizing between primary cytoreductive surgery with or withou … Ended recruitment
  2023-509049-11-00 5 2020-01-01 FIGO stage III ovarian cancer who are eligible for primary cytoreducti
• HOVON 156 AML: Treatment for acute myeloid leukemia (AML) or myelodysplastic syndrome with a FLT3 mutation with gilteritinib or midostaurin … Ended recruitment
  2022-502478-18-00 4 2019-12-20 Acute Myeloid Leukemia (AML)
• A randomized phase II multicenter study to assess the tolerability and efficacy of the addition of midostaurin to 10-day decitabine in unfit … Ended recruitment
  2023-503829-18-00 4 2019-12-05 Acute myeloid leukemia
• A study to determine whether the addition of Dostarlimab (TSR-042) delays recurrence of advanced endometrial cancer Ended recruitment
  2023-506551-23-00 5 2019-11-21 Recurrent or primary advanced (Stage III or IV) endometrial cancer
• A randomized phase II study of second line treatment with liposomal irinotecan and S1 versus liposomal irinotecan and 5-fluorouracil in pati … Ended recruitment
  2023-509463-24-01 4 2019-11-04 metastatic pancreatic cancer
• This is a randomized, double-blind, controlled trial to evaluate the efficacy and safety of cabozantinib in combination with nivolumab and i … Ended recruitment
  2024-515616-47-00 5 2019-10-03 Metastatic Renal Cell Carcinoma
• A trial to learn if different cancer treatment combinations are safe and work in people with advanced non-small cell lung cancer that has mu … Ended recruitment
  2023-504624-25-00 4 2019-09-26 Advanced Non-Small Cell Lung Cancer
• Efficacy and Safety of M281 in Adults with Warm Autoimmune Hemolytic Anemia: A Multicenter, Randomized, Double-blind, Placebo-controlled Stu … Ended recruitment
  2023-505321-14-00 10 2019-09-06 Warm Autoimmune Hemolytic Anemia
• Study for patients with Primary Hyperoxaluria to evaluate the Long-Term Safety and Efficacy of DCR-PHXC Solution for Injection Ended recruitment
  2024-512260-54-00 5 2019-08-20 Primary Hyperoxaluria
• EORTC-1537-LYMG: Very early FDG-PET-response adapted targeted therapy for advanced Hodgkin lymphoma: a single-arm phase II study Ended recruitment
  2023-508478-27-00 4 2019-07-30 Advanced stage Hodgkin Lymphoma
• A phase 3B, open-label, single-arm, rollover study to evaluate long-term safety of Luspatercept in subjects who have participated in other L … Ended recruitment
  2022-502498-40-00 5 2019-07-26 myelodysplastic syndrome (MDS); beta (β)-thalassemia (THAL); myelofibr
• A study of androgen deprivation therapy (ADT) plus apalutamide in patients with prostate cancer Ended recruitment
  2023-506153-38-00 5 2019-07-11 High-risk localized or locally advanced prostate cancer
• Liposomal iRInotecan, Carboplatin or oXaliplatin in the first line treatment of esophagogastric cancer: a randomized phase 2 study (LyRICX) Ended recruitment
  2023-509287-26-00 4 2019-07-01 previously untreated metastatic or locally advanced esophagogastric ca
• A Study to Evaluate MEDI5752 in Subjects with Advanced Solid Tumors Ended recruitment
  2023-509605-77-00 1 2019-06-27 Advanced solid tumours
• A Phase 3 Study to compare how effective and safe DCC-2618 is versus sunitinib in patients with GIST who have been treated previously with i … Ended recruitment
  2024-513277-52-00 5 2019-05-20 Patients with Advanced Gastrointestinal Stromal Tumors

Showing 817–840 of 1,112 trials